ClinicalTrials.gg
RecruitingNCT06089083PROOFUpdated Jan 26, 2026

PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery

An observational study in Malignant Female Reproductive System Neoplasm, Gynecologic Cancer and Gynecologic Neoplasm, sponsored by University of California, San Francisco. Recruiting at 2 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by University of California, San Francisco · Observational

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 37 studies in Genital Neoplasms, Female with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Genital Neoplasms, Female · United States.

Started
2023
with 2 others
Observational
4 of 37
2 open now
Registered
32nd of 37
by date

Among the 37 studies in Genital Neoplasms, Female with a site in United States, this one is one of 3 that started in 2023, is one of 4 observational ones, and was the 32nd registered.

Genital Neoplasms, Female

81 studies on the registry are indexed under Genital Neoplasms, Female; 18 are open to participants now.

Browse Genital Neoplasms, Female studies →

Open to participants now

6 of the 37 studies in Genital Neoplasms, Female with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Genital Neoplasms, Female studies recruiting now, 8 (57%) set no upper age limit and 5 (36%) stop at 75 or younger; 1 takes children under 18; 2 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies in Genital Neoplasms, Female with a site in United States, or all of them as a file.
02

Study summary

This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.

Read the detailed description

PRIMARY OBJECTIVE:

I. Assess the risk factors associated with frailty in newly diagnosed gynecologic cancer participants.

SECONDARY OBJECTIVES:

I. Compare primary quality of life endpoint of "healthy days at home" between non-frail and frail participants (primary quality of life endpoint).

II. Compare other perioperative, oncologic, and quality of life outcomes between non-frail and frail participants.

OUTLINE: This is an observational study.

All new patients being evaluated for a new diagnosis of gynecologic cancer by the University of California, San Francisco (UCSF) Gynecologic Oncology service and the Dana-Farber Cancer Institute will be recruited in both the outpatient or inpatient setting. Study participants will be enrolled at the time of diagnosis and followed for up to one year after undergoing surgery for cancer.

03

Conditions studied

  • Malignant Female Reproductive System Neoplasm
  • Gynecologic Cancer
  • Gynecologic Neoplasm

Keywords

  • Frailty
  • Risk Factors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Women undergoing evaluation for a newly diagnosed gynecologic malignancy

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 years or greater
  • Undergoing evaluation for a newly diagnosed gynecologic
  • Ability of individual or legal guardian/representative to understand a written document, and the willingness to sign it

Exclusion criteria

Exclusion Criteria:

  • to any study-related procedure or assessment
  • Does not speak a language for which the consent form and study materials are available
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Groups and cohorts

  • Newly diagnosed gynecologic cancer

    Participants will undergo physical function assessments, complete surveys, and medical records every 3 months +/- 4 weeks prior to standard of care surgery (outside of this protocol). After surgery subjects will be followed for at least 3 months +/- 4 weeks for up to one year after diagnosis. Medical record reviews will occur periodically to examine for long-term follow up oncologic outcomes of progression free survival, overall survival, and chemotherapy delays for up to 10 years after enrollment.

    Other: Physical function assessment · Other: Self-reported Assessments and Questionnaires · Procedure: Surgery (Standard of Care, Non-Interventional)

Interventions

  • OtherPhysical function assessment

    Physical assessments of frailty will be conducted in person.

  • OtherSelf-reported Assessments and Questionnaires

    Quality of life questionnaires and self-reported measures will be provided to complete during the course of the study

    Also known as: Questionnaires

  • ProcedureSurgery (Standard of Care, Non-Interventional)

    Surgical data will be reviewed via medical record

    Also known as: Surgical Procedure

06

What researchers measure

Primary outcomes

  1. Proportion of participants who are categorized as frail

    The Fried frailty phenotype (FP) assesses physical frailty through five criteria: unintentional weight loss; weakness or poor handgrip strength; self-reported exhaustion; slow walking speed; and low physical activity. Participants who receive a score of \>3 will be categorized as 'frail'. Participants who receive a score \<=3 will be categorized as Non-frail at time of enrollment.

    Time frame: At time of enrollment, 1 day

  2. Demographic risk factors associated with those who screen positive for frailty

    Demographic risk factors obtained from medical record review (i.e. sex, age, race, ethnicity, cancer type, cancer histology, cancer stage, comorbidities, etc.) will be assessed and analyzed for differences between participants categorized as frail versus non-frail.

    Time frame: At time of enrollment, 1 day

  3. Oncologic risk factors associated with those who screen positive for frailty

    Risk factors determined to be oncologic in nature will be assessed and analyzed for differences between participants categorized as frail versus non-frail.

    Time frame: At time of enrollment, 1 day

Secondary outcomes

  1. Mean number of healthy days at home

    The number of healthy days at home is defined as healthy days at home is defined as: 365 days minus (1) mortality days, (2) total number of days spent in inpatient, observation, skilled nursing facilities (SNF), rehabilitation, long-term hospital settings, emergency department and will be summarized and used as covariate in analysis.

    Time frame: Up to 10 years

  2. Mean length of hospital stay

    The number of days participants stay in the hospital following standard of care surgery for gynecological cancer will be summarized and used as covariate in analysis.

    Time frame: Up to 10 years

  3. Percentage of participants readmitted to hospital

    Participants with documented re-admission to a hospital following standard of care surgery for gynecological cancer will be summarized and used as a covariate in analysis.

    Time frame: Up to 10 years

  4. Percentage of participants with reported surgical complications

    Participants with documented peri-operative complications following standard of care surgery for gynecological cancer will be summarized and used as a covariate in analysis.

    Time frame: Up to 10 years

  5. Mean time to initiation of standard of care chemotherapy

    The median number of days following standard of care surgery for gynecological cancer to first standard of care chemotherapy initiation will be summarized and used as a covariate in analysis.

    Time frame: Up to 10 years

  6. Median Progression Free Survival (PFS)

    Progression free survival is defined as the time from date of diagnosis to date of radiographic progression, and/or doubling of cancer antigen 125 (CA-125) from baseline.

    Time frame: Up to 10 years

  7. Median Overall Survival (OS)

    Overall survival as defined by days from date of diagnosis to date of death, or study completion whichever occurs first.

    Time frame: Up to 10 years

  8. Mean number of treatment delays

    Chemotherapy delays is defined by the number of chemotherapy infusions that are delayed due for medical purposes and the total number of days infusions are delayed for will be summarized and used as a covariate in analysis.

    Time frame: Up to 10 years

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Nov 2027, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2023
First posted
Oct 18, 2023
StartActual
Oct 18, 2023
Primary completionEst.
Nov 30, 2027
CompletionEst.
Nov 30, 2033
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06089083
Collaborators
Conquer Cancer Foundation, American Society of Clinical Oncology, National Institute on Aging (NIA), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Responsible party
Sponsor
First posted
Oct 18, 2023
Start date
Oct 18, 2023
Primary completion
Nov 30, 2027 (estimated)
Completion
Nov 30, 2033 (estimated)
Last update
Jan 26, 2026

Study contacts

Janet Titzler
Contact
janet.titzler@ucsf.edu
415-353-9600
Stephanie Cham, MD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion